Lisata Q3 net loss $5.3M; ASCEND ~95% enrolled, BOLSTER first patients treated

LISATA THERAPEUTICS, INC.

2023-Q3 EPS reported -$1.92

Net loss of $5.3M in Q3 2023 (vs $37.4M prior year which included $30.4M merger costs); cash $54.4M.
ASCEND study (~95% enrollment) received positive interim futility analysis; topline data from Cohort A expected as early as Q4 2024.
First patients treated in BOLSTER basket trial for head and neck and cholangiocarcinoma cohorts.
Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and pancreatic cancer (EU).
Cash runway into early 2026; expected to fund all ongoing trials through data.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

LISATA THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-23-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.